Phospho-MCL-1 (Ser159) Mouse anti-Human, Mouse, PE, Clone: RBCERNR, eBioscience™ Invitrogen™
Mouse Monoclonal Antibody
This RBCERNR MAb recognizes human and mouse myeloid cell leukemia sequence 1 (Mcl-1) when phosphorylated on serine 159 (S159). Mcl-1 is an anti-apoptotic protein that is a member of the Bcl-2 family of proteins important for regulation of cell survival/apoptosis. Mcl-1 is primarily localized to the outer membrane of mitochondria where it prevents cytochrome c release via dimerization with other Bcl-2 family members such as Bim. PI3K activation of AKT results in the phosphorylation of GSK3 beta at serine 9 (S9) resulting in destabilization and degradation of GSK3 beta. Loss of GSK3 beta prevents phosphorylation of Mcl-1 on S159 and its subsequent ubiquitnation and degradation. Mice conditionally lacking Mcl-1 in lymphocytes showed that Mcl-1 is essential during early lymphoid development and for the maintenance of mature lymphocytes.Phospho-MCL-1 (Ser159) Monoclonal antibody specifically detects Phospho-MCL-1 (Ser159) in Human, Mouse samples. It is validated for Flow Cytometry
|AW556805; BCL2 family apoptosis regulator; BCL2L3; bcl2-L-3; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; EAT; Induced myeloid leukemia cell differentiation protein Mcl-1; induced myeloid leukemia cell differentiation protein Mcl-1 homolog; MCL1; Mcl-1; mcl1/EAT; MCL1-ES; MCL1L; MCL1S; MCL-1S; MGC104264; MGC1839; myeloid cell leukemia 1; myeloid cell leukemia ES; myeloid cell leukemia sequence 1; myeloid cell leukemia sequence 1 (BCL2-related); TM|
|4° C, store in dark, DO NOT FREEZE!|
|PBS with 0.2% BSA and 0.09% sodium azide; pH 7.2|
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok